Anti-CD19 Reference Antibody (inebilizumab)
- Product Code: 139859
| Molecular Weight: | Molecular Formula: | ||
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Used primarily in the treatment of autoimmune neurological disorders, particularly neuromyelitis optica spectrum disorder (NMOSD). It targets CD19-positive B cells, leading to their rapid and sustained depletion, which helps prevent immune-mediated damage to the central nervous system. The antibody is especially effective in patients who are aquaporin-4 antibody positive, reducing the risk of relapses and disease progression. Its application allows for a more targeted immunosuppressive approach with a favorable safety profile compared to broad immunosuppressants.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 50μg | 10-20 days | $232.79 |
+
-
|
Anti-CD19 Reference Antibody (inebilizumab)
Used primarily in the treatment of autoimmune neurological disorders, particularly neuromyelitis optica spectrum disorder (NMOSD). It targets CD19-positive B cells, leading to their rapid and sustained depletion, which helps prevent immune-mediated damage to the central nervous system. The antibody is especially effective in patients who are aquaporin-4 antibody positive, reducing the risk of relapses and disease progression. Its application allows for a more targeted immunosuppressive approach with a favorable safety profile compared to broad immunosuppressants.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
$0.00
$0.00
Total :